Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

doi:10.1200/JCO.2015.61.5005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2015

Sandmann Thomas, Bourgon Richard, Garcia Josep, Li Congfen, Cloughesy Timothy, Chinot Olivier L, Wick Wolfgang, Nishikawa Ryo, Mason Warren, Henriksson Roger, Saran Frank, Lai Albert, Moore Nicola, Kharbanda Samir, Peale Franklin, Hegde Priti, Abrey Lauren E, Phillips Heidi S, Bais Carlos

Abstract excerpt

PURPOSE: The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide. To establish whether certain patient subgroups derived an OS benefit from the addition of bevacizumab to first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Alkylating

Share to Bevacizumab

Share to Clinical Trials, Phase III as Topic

Share to Dacarbazine

Share to Radiotherapy, Adjuvant

Share to Randomized Controlled Trials as Topic

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 26124478
DOI: 10.1200/JCO.2015.61.5005
PMCID: PMC5015426

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.PMID 26124478Read ↗

Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.Semantic proximity Read ↗

Clinical Stratification of Glioblastoma Based on Alterations in Retinoblastoma Tumor Suppressor Protein (RB1) and Association With the Proneural SubtypeSemantic proximity Read ↗

The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.Semantic proximity Read ↗

PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.Semantic proximity Read ↗

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger ageSemantic proximity Read ↗

Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutationSemantic proximity Read ↗

Higher vascularity at infiltrated peripheral edema differentiates proneural glioblastoma subtypeSemantic proximity Read ↗

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.Semantic proximity Read ↗

The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma.Semantic proximity Read ↗

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.